These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy. Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521 [TBL] [Abstract][Full Text] [Related]
3. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. Culine S; Kramar A; Théodore C; Geoffrois L; Chevreau C; Biron P; Nguyen BB; Héron JF; Kerbrat P; Caty A; Delva R; Fargeot P; Fizazi K; Bouzy J; Droz JP; J Clin Oncol; 2008 Jan; 26(3):421-7. PubMed ID: 18202419 [TBL] [Abstract][Full Text] [Related]
4. Management of good risk germ-cell tumours. Troost MM; Sternberg CN; de Wit R BJU Int; 2009 Nov; 104(9 Pt B):1387-91. PubMed ID: 19840018 [TBL] [Abstract][Full Text] [Related]
5. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. Motzer RJ; Nichols CJ; Margolin KA; Bacik J; Richardson PG; Vogelzang NJ; Bajorin DF; Lara PN; Einhorn L; Mazumdar M; Bosl GJ J Clin Oncol; 2007 Jan; 25(3):247-56. PubMed ID: 17235042 [TBL] [Abstract][Full Text] [Related]
6. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Droz JP; Kramar A; Biron P; Pico JL; Kerbrat P; Pény J; Curé H; Chevreau C; Théodore C; Bouzy J; Culine S; Eur Urol; 2007 Mar; 51(3):739-46; discussion 747-8. PubMed ID: 17084512 [TBL] [Abstract][Full Text] [Related]
7. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group. Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C; J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869 [TBL] [Abstract][Full Text] [Related]
8. The importance of the dose of etoposide in the initial treatment of metastatic germ cell tumors and advances in management of patients that relapse. Marwaha S; Venner PM; North SA Can J Urol; 2007 Oct; 14(5):3692-6. PubMed ID: 17949524 [TBL] [Abstract][Full Text] [Related]
9. [Carboplatin-etoposide-bleomycine chemotherapy protocol in the treatment of patients with metastatic non-seminomatous germ-cell testicular tumours with good prognosis]. Jeremić B; Djurić Lj; Djordjević S; Cirović V; Milojević Lj; Stanisavljević B; Matović M; Mijatović Lj Srp Arh Celok Lek; 1994; 122(9-10):257-9. PubMed ID: 17977429 [TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy for metastatic germ cell tumours of the testis]. Culine S Rev Prat; 2007 Feb; 57(4):385-8. PubMed ID: 17455740 [TBL] [Abstract][Full Text] [Related]
11. Paclitaxel, bleomycin, etoposide, and cisplatin (T-BEP) as initial treatment in patients with poor-prognosis germ cell tumors (GCT): a phase II study. Mardiak J; Sálek T; Sycová-Milá Z; Obertová J; Recková M; Mego M; Hlavatá Z; Brozmanová K; Risnyovzská Z; Svetlovská D; Koza I Neoplasma; 2007; 54(3):240-5. PubMed ID: 17447857 [TBL] [Abstract][Full Text] [Related]
12. [Management of localized germ-cell tumours of the testis]. Loriot Y; Fizazi K Rev Prat; 2007 Feb; 57(4):379-84. PubMed ID: 17455739 [TBL] [Abstract][Full Text] [Related]